TLDR
- Xylem reported Q1 EPS of $1.12, beating the $1.09 analyst estimate
- Revenue came in at $2.1 billion, slightly missing the $2.11 billion estimate
- New orders totaled $2.2 billion, up 3% year over year
- Full-year 2026 revenue guidance raised to $9.2B–$9.3B
- Stock was up 1.6% in premarket trading ahead of Tuesday’s open
Xylem posted a mixed but broadly positive Q1 report Tuesday morning, with earnings coming in ahead of expectations even as revenue narrowly missed.
$XYL Q1 2026 earnings: Steady Margins Mask a Stagnant Top Line
Xylem delivered a technically solid but uninspiring first quarter. Revenue and orders were completely flat organically (0% growth), absorbing the intentional headwinds from management's ongoing 80/20 portfolio…
— Finsee (@Finsee_main) April 28, 2026
The water technology company reported adjusted EPS of $1.12 for the first quarter, beating the Wall Street consensus of $1.09. That compares to $1.03 a year ago.
Revenue hit $2.1 billion, up 3% year over year on a reported basis. Organically — stripping out currency moves and acquisitions — revenue was flat. Analysts had expected $2.11 billion, so it was a slim miss on the top line.
New orders came in at $2.2 billion, up 3% year over year on a reported basis, though flat on an organic basis. Orders running ahead of revenue is generally a healthy sign for near-term demand.
Adjusted EBITDA margin expanded 20 basis points year over year to 20.6%. Xylem credited productivity savings and pricing gains, which offset inflation and softer volumes.
CEO Matthew Pine struck a measured tone. “We entered the year with sustained momentum and solid demand across key end markets,” he said. “While the external environment remains dynamic, our teams are executing well, staying close to customers, and advancing long-term priorities.”
Guidance Gets a Modest Bump
Xylem nudged its full-year 2026 revenue outlook higher. The company now expects $9.2 billion to $9.3 billion, up from prior guidance of $9.1 billion to $9.2 billion. That represents 2% to 3% growth on a reported basis.
Full-year adjusted EPS guidance was held steady at $5.35 to $5.60. The midpoint of $5.48 sits just a hair below the analyst consensus of $5.49.
The company also expects full-year adjusted EBITDA margin of 22.9% to 23.3%, which would be an improvement of 70 to 110 basis points from 2025 results.
Jefferies analyst Stephen Volkmann described the quarter as “in line.” Not a ringing endorsement, but the market seemed to take it as good enough.
Where the Stock Stands
Xylem stock was up 1.6% in premarket trading, touching $125.50, even as broader futures pointed slightly lower.
Coming into Tuesday, XYL was down 9% year to date and up just 6% over the past 12 months. The stock dropped 8% after its Q4 report in February.
First quarter reported EPS came in at $0.79, up 14% from $0.69 in the same period last year.
The Q1 numbers at least stopped the bleeding for now.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
